Sunshine Novo (688621.SH): Phase I clinical trial of STC008 injection for cancer cachexia in advanced solid tumors achieves expected goals.

Zhitong Finance APP News, Sunshine Novo (688621.SH) announced that recently, the Phase I clinical trial of STC008 Injection (project code "STC008"), independently developed by the company's wholly-owned subsidiary Chengdu Novo Shengtai Biotechnology Co., Ltd. (hereinafter referred to as "Novo Shengtai"), for the treatment of cancer cachexia in advanced solid tumors, achieved its expected goals.